Price Alert

Insmed (INSM)

NASDAQ: INSM · Real-Time Price · USD

144.59

-2.61 (-1.77%)

At close: Sep 10, 2025, 12:28 PM

-1.77% (1D)

Bid	144.53
Market Cap	30.56B
Revenue (ttm)	398.11M
Net Income (ttm)	-1.03B
EPS (ttm)	-5.67
PE Ratio (ttm)	-25.5
Forward PE	-38.7
Analyst	Strong Buy

Ask	144.67
Volume	511,181
Avg. Volume (20D)	3,673,212
Open	148.15
Previous Close	147.20
Day's Range	144.34 - 148.32
52-Week Range	60.40 - 149.08
Beta	0.97

About INSM

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol INSM

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for INSM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Insmed is scheduled to release its earnings on Oct 30, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 weeks ago

+3.97%

Insmed shares are trading higher after Stifel and ... Unlock content with Pro Subscription

4 weeks ago

+8.07%

Insmed shares are trading higher after the company announced it received FDA approval for BRINSUPRI.

News

4 days ago · seekingalpha.com

Insmed Incorporated (INSM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Insmed Incorporated (NASDAQ:INSM ) Wells Fargo 20th Annual Healthcare Conference 2025 September 5, 2025 8:00 AM EDT Company Participants Sara Bonstein - Chief Financial Officer Conference Call Partici...

3 weeks ago · benzinga.com

Lung Disease-Focused Insmed 'Must-Own' Name For Investors

William Blair initiated coverage on Insmed Incorporated INSM, citing that the clinical and commercial execution of its drugs can significantly increase Insmed's valuation.

3 weeks ago · youtube.com

Josh Brown's Best Stocks in the Market: Insmed

Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to detail his latest addition to his 'Best Stocks in the Marlet,' Insmed.

3 weeks ago · https://thefly.com

Insmed price target raised to $145 from $121 at Stifel

Stifel raised the firm's price target on Insmed to $145 from $121 and keeps a Buy rating on the shares following FDA's recent approval of Brinsupri as the first approved therapy for treatment of non-C...

4 weeks ago · youtube.com

Insmed CEO on what's next for company after FDA greenlights lung disease drug

Will Lewis, Insmed CEO, joins 'Fast Money' to discuss the company's lung drug being greenlit by the FDA and what it means for for the stock.

4 weeks ago · benzinga.com

FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease

The U.S. Food and Drug Administration (FDA) on Tuesday approved Insmed Incorporated's INSM Brinsupri (brensocatib 10 mg and 25 mg tablets). It is an oral, once-daily treatment for non-cystic fibrosis ...

4 weeks ago · reuters.com

US FDA approves Insmed's lung disease drug

The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday, making it the first treatment for the chronic condition.

4 weeks ago · zacks.com

Don't Overlook Insmed (INSM) International Revenue Trends While Assessing the Stock

Explore Insmed's (INSM) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

1 month ago · seekingalpha.com

Insmed Incorporated (INSM) Q2 2025 Earnings Call Transcript

Insmed Incorporated (NASDAQ:INSM ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Bryan Dunn - Vice President of Investor Relations Martina Flammer - Chief Medical Off...

1 month ago · zacks.com

Insmed (INSM) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Insmed (INSM) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates ...

Load More News